Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries
- PMID: 35243386
- PMCID: PMC8883191
- DOI: 10.1016/j.euros.2021.12.003
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries
Abstract
The International Kidney Cancer Coalition (IKCC) is a federation of 46 affiliated patient organisations representing 1.2 million patients worldwide that is committed to reducing the global burden of kidney cancer. A large-scale global survey of patients with renal cell carcinoma (RCC) to capture real-world experiences has never been undertaken. The 35-question survey was designed to identify geographic variations in patient education, experience, awareness, access to care, best practices, quality of life, and unmet psychosocial needs. A total of 1983 responses were recorded from 43 countries in 14 languages. Analysis revealed key findings. (1) At diagnosis, 43% of all respondents had no understanding of their RCC subtype. (2) Shared decision-making remains aspirational: globally, 29% of all patients reported no involvement in their treatment decision, responding "My doctor decided for me". (3) While 96% of respondents reported psychosocial impacts, surprisingly, only 50% disclosed them to their health care team. (4) Lastly, 70% of patients were not asked to participate in a clinical trial, although 90% indicated they would be interested. The survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. The data point to actionable deficits in the fields of clinical trials, psychosocial support, and shared decision-making.
Patient summary: In this brief report, we highlight the key results from the first large-scale global survey of patients with kidney cancer to capture real-world experiences. This survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. We conclude that there is a need for improvement in the fields of clinical trials, psychosocial support, and shared decision-making.
Keywords: Clinical trials; Kidney cancer; Patient-reported experience; Psychosocial support; Shared decision-making.
© 2021 Published by Elsevier B.V. on behalf of European Association of Urology.
Figures
Comment in
-
Urological Oncology: Adrenal, Renal, Ureteral and Retroperitoneal Tumors.J Urol. 2022 Aug;208(2):472-474. doi: 10.1097/JU.0000000000002763. Epub 2022 May 20. J Urol. 2022. PMID: 35593061 No abstract available.
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.JBI Database System Rev Implement Rep. 2015 Jan;13(1):99-111. doi: 10.11124/jbisrir-2015-1809. JBI Database System Rev Implement Rep. 2015. PMID: 26447011
-
A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.JBI Libr Syst Rev. 2012;10(58):4633-4646. doi: 10.11124/jbisrir-2012-432. JBI Libr Syst Rev. 2012. PMID: 27820528
-
Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass.Eur Urol. 2021 Nov;80(5):575-588. doi: 10.1016/j.eururo.2021.01.021. Epub 2021 Feb 6. Eur Urol. 2021. PMID: 33558091 Review.
-
The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review.J Urol. 2021 Oct;206(4):827-839. doi: 10.1097/JU.0000000000001901. Epub 2021 Jun 11. J Urol. 2021. PMID: 34111958
Cited by
-
Cross-sectional study of therapy-related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan.Cancer Med. 2024 Jun;13(11):e7196. doi: 10.1002/cam4.7196. Cancer Med. 2024. PMID: 38872405 Free PMC article.
-
The evolving management of small renal masses.Nat Rev Urol. 2024 Jul;21(7):406-421. doi: 10.1038/s41585-023-00848-6. Epub 2024 Feb 16. Nat Rev Urol. 2024. PMID: 38365895 Review.
-
Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study.ESMO Open. 2025 Jun;10(6):105115. doi: 10.1016/j.esmoop.2025.105115. Epub 2025 May 23. ESMO Open. 2025. PMID: 40412006 Free PMC article. Clinical Trial.
-
Patient experience of follow-up after surgery for kidney cancer: a focus group study.BJU Int. 2023 Jul;132(1):47-55. doi: 10.1111/bju.15982. Epub 2023 Feb 22. BJU Int. 2023. PMID: 36726216 Free PMC article.
-
Wellbeing status and priority concerns of patients with advanced renal cell carcinoma: results of the EONS PROMs project international online survey.Support Care Cancer. 2025 Jun 3;33(6):531. doi: 10.1007/s00520-025-09585-5. Support Care Cancer. 2025. PMID: 40456970 Free PMC article.
References
-
- Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. - PubMed
LinkOut - more resources
Full Text Sources